HEPA · Hepion Pharmaceuticals, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Due to our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern within one year of the issuance of these condensed consolidated financial statements without additional capital becoming available to us.”View the 10-Q filed Aug 13, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Mar 18, 2025; bars on opposite sides are not compared.
The closing range begins at the captured split on Mar 18, 2025.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HEPA
this stock
Hepion Pharmaceuticals, Inc.
|
$6.77M | — | — | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$140.51B | +20.8% | +46.2% | 32.3 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.82B | +6.7% | +20.8% | 20.4 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.3% | — | — | 1.9% |
|
MRNA
Moderna, Inc.
|
$61.59B | +423.1% | +4.3% | — | 13.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.0%
- Net QoQ
- 0 sh
- Top holder
- Ancora Advisors LLC
Performance
Raw-price comparisons begin at the captured split on Mar 18, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HEPA | -58.3% | -64.9% | — | -53.3% | — |
| SPY | +5.0% | +8.9% | +0.2% | +5.8% | +0.1% |
| vs SPY | -63.4% | -73.8% | — | -59.1% | — |